Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 448-300-4 | CAS number: 88642-03-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- Expert Statement
- Type of information:
- other: Expert Statement
- Adequacy of study:
- key study
- Study period:
- 2019-02-14
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Expert statement, no other study available
Data source
Reference
- Reference Type:
- other: Expert Statement
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2019
Materials and methods
- Principles of method if other than guideline:
- Expert Statement
- GLP compliance:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 448-300-4
- EC Name:
- -
- Cas Number:
- 88642-03-9
- Molecular formula:
- C16H28O
- IUPAC Name:
- (6E)-cyclohexadec-6-en-1-one; (7Z)-cyclohexadec-7-en-1-one; (8E)-cyclohexadec-8-en-1-one; (8Z)-cyclohexadec-8-en-1-one
Constituent 1
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Inhalation
The low water solubility (<1 mg/L) and high lipophilicity (log Pow = 6.5) indicate that the substance may be retained in the mucus and indicates a potential for accumulation. However, due to the low volatility (vapour pressure = 0.0092 Pa) and the susceptibility to convert to the molten state in view of the very low melting point (= 25°C) tendency, the potential for inhalation of dust or vapours is only marginal.
Oral
The test item has a low water solubility (<1 mg/L) and is highly lipophilic, and therefore may not readily dissolve in gastrointestinal fluid and absorption by passive diffusion will be very limited. Furthermore, no toxicity was observed in the acute oral toxicity study and in the subchronic oral toxicity study up to 1000 mg/kg bw. Systemic absorption does not seem to be a preferential route of entry into the body.
Dermal
Due to the low water solubility (<1 mg/L) and a logPow of 5.8, dermal uptake is likely to be low. Since the substance is a skin irritant, damage to the skin surface may enhance penetration. However, the lack of toxicity in the acute dermal toxicity study up to a dose of 2000 mg/kg bw may be seen as an indication that this is not a preferential route of entry into the body. - Details on distribution in tissues:
- During the 28-day oral toxicity study in the rat only marginal changes in cholesterol levels and liver weights were observed, which indicate that the liver can be considered as target organ. However, the histopathological examination revealed no changes on cellular level. The results of the examinations indicate that following the repeated administration of high doses sufficient amounts are resorbed, as indicated by the marginal reaction of the liver. Apart from that, no signs of systemic toxicity could be observed.
- Details on excretion:
- The available data do not allow the prediction of an expected metabolism or excretion of the substance.
Metabolite characterisation studies
- Details on metabolites:
- It can be assumed that P450-enzymes are substantially involved in the metabolism of the test item, since in the chromosome aberration test with human lymphocytes clear toxic effects were observed after 4 h and 22h treatment with 49 µg/mL and above in the absence of S9 mix, whereas no cytotoxic effects could be observed after 4h treatment up to the highest applied concentration in the presence of S9 mix. The available data do not allow the prediction of an expected metabolism or excretion of the substance. Metabolism by Phase I enzymes, such as CYP450 enzymes, usually aims to enhance hydrophilicity of the substance by for example hydroxylation. Thus, the test item is not considered of concern in regards to bioaccumulation, since it is anticipated that it is metabolised to more hydrophilic metabolites in the organism.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.